The FDA on 23 September gave Celgene the go-ahead to market Otezla (apremilast), a selective inhibitor of phosphodiesterase 4 (PDE4), to treat moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
The drug is the first and only PDE4 inhibitor approved in plaque psoriasis, a chronic inflammatory disease of the skin,...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
